Disclosed herein are medical devices, such as stents, comprising a porous substrate, such as a porous ceramic. Also disclosed herein are methods for impregnating the porous substrate with a composition comprising at least one lipid and at least one pharmaceutically active agent, where the porous substrate is microporous and/or nanoporous.
Disclosed herein are medical devices, such as stents, comprising a porous substrate, and a composition coating and/or impregnating the porous substrate where the composition comprises a bioresorbable carrier (e.g., at least one lipid) and at least one pharmaceutically active agent.
Disclosed herein are medical devices, such as stents, coated with calcium phosphate and processes for making the same. The stent can comprise a cobalt chromium alloy that has been treated to improve surface adhesion to the calcium phosphate and/or improve surface finish properties. A pharmaceutically active agent can be present in the calcium phosphate coating.
Disclosed herein are solid film coatings for implantable medical devices comprising a solid film covering at least a portion of the device. The solid film comprises: at least one lipid selected from cholesterol and cholesterol derivatives, at least one additional solid lipid other than cholesterol and cholesterol derivatives, and a therapeutically effective amount of at least one pharmaceutically active agent. Also disclosed herein are methods of preparing film coatings and methods of treating diseases with the implantable devices.
A61L 31/16 - Biologically active materials, e.g. therapeutic substances
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 9/00 - Medicinal preparations characterised by special physical form
Disclosed herein are medical devices, such as implantable devices (e g stents), comprising at least one coating covering at least a portion of the device in the form of film. The film may be a dry film and comprise at least one lipid bilayer and at least one pharmaceutically effective agent. Alternatively, the film may comprise at least one lipid, not necessarily in bilayer form, and at least one pharmaceutically effective agent. When the devices comprising the at least one lipid bilayer are exposed to an aqueous fluid, liposomes are released,encapsulating the pharmaceutically effective agent. The coatings may be placed directly on the device, or applied to a substrate attached to the device.
This application relates to a drug delivery composition comprising a nonpolymeric, solidified matrix and a drug dispersed in the matrix. The matrix material comprises an organic metal salt or silica or titania, or a combination thereof. In one embodiment the drug is substantially uniformly dispersed in the matrix in a particulate form. The matrix material encapsulates the drug particles and controls its release in vivo. Optionally a biodegradable lipid layer may be applied to the matrix. The drug delivery composition may be applied to the surface of a medical device, such as a cardiovascular stent, or may be formulated as a pharmaceutical preparation suitable for other means of administration. Methods of forming the composition are described which enable in situ encapsulation of both water-insoluble and water-soluble drugs.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Disclosed herein are electrolyte solutions and methods for electrolytic co-deposition of calcium phosphate and drug composites. The electrolyte solution may be formed by mixing solutions comprising calcium and phosphate precursors together to form an electrolyte solution. The electrolyte solution can have a water content less than 30 weight percent. The electrolyte solution may comprise a water-soluble non-aqueous solvent. A therapeutic agent, such as water-insoluble drug, is also present in the solution. The electrolyte solution thus formed may be used to co-deposit a calcium phosphate coating and the therapeutic agent on a substrate. One method includes the steps of immersing the substrate in the electrolyte solution and applying an electrical potential to the substrate to thereby cause (i) the calcium and phosphate precursors to electrochemically react with hydroxyl groups on the surface of the substrate and deposit the calcium phosphate coating thereon; and (ii) the therapeutic agent to electrophoretically migrate to the substrate and become co-deposited thereon together with the calcium phosphate coating. The method thus provides a convenient and easily controllable means for depositing thin film calcium phosphate and drug composites on substrates such as implantable medical devices.
This application relates to a composition comprising a mixture of different organic solvents formulated for controlled drug release. The release profile of the drug can be regulated by adjusting the compositional ratios of the solvents. In one embodiment of the invention a first solvent is water-soluble and a second solvent is water-insoluble. The first and second solvents are miscible and together form a solution containing the drug. The hydrophobicity of the composition can be adjusted by altering the relative amount of the second solvent. The composition also includes a solid lipid dissolved in the drug-containing solution. In aqueous environments the lipid may precipitate to form a thin membrane in an outer surface portion of the composition, thereby further regulating the release of the drug. The membrane is preferably renewable. That is, as the outermost portion of the lipid is biodegraded at a target location in vivo, additional outer portions of the lipid precipitate to renew the thin membrane. The composition may be formulated, for example, as a suspension, nanoparticle, microparticle, paste or thin film coating. In one particular embodiment, the composition may be applied to an implantable medical device, such as a cardiovascular stent.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
patents
